Zhang et al. [12] performed hybrid capture-based next-generation sequencing on 64 primary and 17 recurrent tumor samples, revealing more copy number variations, co-occurrence of IDH1 and TERT mutations, inactivated cell cycle signaling, and a higher tumor mutation burden in recurrent tumors. This evidence concerns the gene IDH1 and neoplasm.